HER2 mutations, which account for 2–4% of non-small cell lung cancer (NSCLC), are
distinct molecular alterations identified via next generation sequencing (NGS). Previously …

Simple Summary There are growing data on targeting HER2 alterations, which include gene
mutations, gene amplifications, and protein overexpression, for non-small cell lung cancer …

While human epidermal growth factor receptor 2 (HER2) aberrations have long been
described in patients with non-small cell lung cancer (NSCLC), they have only recently been …

Epidermal growth factor receptor 2 (HER2/ErbB2/neu), a member of ErbB receptor tyrosine
kinase family, forms homo-or heterodimers with ErbB1 (HER1/EGFR), ErbB3 (HER3), or …

PURPOSE HER2 is a critical gene that drives various solid tumors in addition to those of
breast cancer. For example, HER2 plays a role in non–small-cell lung cancer (NSCLC) …

Despite the recent increase in the number of types of treatments, non-small-cell lung cancer
(NSCLC) remains the major cause of death from cancer worldwide. So, there is an urgent …

Oncogenic driver mutations identified in non-small cell lung cancer (NSCLC) have triggered
the development of drugs capable of interfering in intracellular signaling pathways involved …

Oncogenic mutations and amplifications in the erythroblastic oncogene B (ERBB2), or
human epidermal growth factor receptor 2 (HER2), have emerged as distinct oncogenic …

Background HER2-targeted therapy provides survival benefits to HER2-mutant non-small
cell lung cancer (NSCLC). A better understanding of the clinical and genomic …

Over the last two decades HER2 aberrations have been thoroughly investigated as potential
therapeutic targets in advanced non–small cell lung cancer, with relatively modest results …